INTRODUCTION
The identification of oncogenic kinases and small molecules designed to target active, functionally relevant kinases has revolutionized cancer treatment. Frustratingly, although many of these targeted inhibitors initially demonstrate encouraging clinical responses, most patients relapse as a result of primary or acquired resistance. Therapy resistance occurs through target-dependent mechanisms resulting from point mutations in the kinase domain that mitigate enzyme inhibitor binding or through target-independent mechanisms, such as alternate activation of survival and proliferation pathways (1, 2) . One example involves the FMS-like receptor tyrosine kinase (FLT3). Activating mutations of FLT3 result in its autophosphorylation and initiation of intracellular signaling pathways, which induce abnormal survival and proliferation of leukemic cells (3) (4) (5) (6) . One of the most common mutations in acute myeloid leukemia (AML) involves the internal tandem duplication (ITD) of FLT3, which occurs in ~25% of all cases of newly diagnosed AML and confers a particularly poor prognosis (4, (7) (8) (9) (10) . FLT3 inhibitors (FLT3i) evaluated in clinical studies as monotherapy and combination therapies have shown good initial response rates; however, patients eventually relapse with FLT3i-resistant disease (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The absence of durable remission in patients treated with potent and selective FLT3i highlights the need to identify resistance mechanisms and to develop additional treatment strategies. Several mechanisms contribute to resistance to selective FLT3i, including mutations in the tyrosine kinase domain of FLT3 (20 to 50%) or activation of parallel signaling mechanisms that bypass FLT3 signaling, referred to as adaptive resistance (30 to 50%) (21) (22) (23) . Furthermore, it is possible for both mechanisms to simultaneously occur in different leukemic populations within a single patient (23) . Adaptive resistance of FLT3-ITD AML cells to FLT3i had been attributed to alternate activation of survival and proliferation pathways (1, (24) (25) (26) (27) (28) (29) (30) . However, combined inhibition of Ras/mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K) signaling alongside FLT3 signaling blockade has not been sufficiently effective at eliminating resistant FLT3-ITD AML cells, implicating additional and/or broader mechanisms of adaptive resistance (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . Moreover, multidrug combination regimens present challenges, including synchronized drug exposure and/or cumulative toxicity, which often prevents dosing to therapeutically optimal exposures (43) . Therefore, identification of adaptive resistance mechanisms and development of therapies that concomitantly target the primary oncogenic signaling pathway and the relevant adaptive resistance mechanism will likely yield the best clinical outcomes.
RESULTS

FLT3i induce adaptive resistance in FLT3-ITD AML
To investigate adaptive resistance to FLT3i in FLT3-ITD AML, we cultured an engineered primary CD34 + human cell line expressing MLL-AF9 and FLT3-ITD (MLL-AF9;FLT3-ITD) and an FLT3-ITD AML cell line (MV4;11) in the presence of cytokines overexpressed in the bone marrow (BM) of patients with AML, including interleukin-3 (IL-3), IL-6, stem cell factor (SCF), thrombopoietin (TPO), and FLT3 ligand (FL) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) . This experimental design explored primary adaptive resistance mechanisms occurring immediately after FLT3i treatment. This approach avoids the possibility of subclones acquiring on-target mutations in FLT3, as observed after chronic exposure to FLT3i (54) (55) (56) . The FLT3-ITD AML cell lines were treated with increasing concentrations of AC220 (quizartinib), a selective inhibitor of FLT3 currently in phase 3 clinical evaluation (NCT02668653), for 72 hours and then examined for leukemic cell recovery (Fig. 1A) . Quizartinib treatment at the indicated doses decreased the viability of FLT3-ITD AML cell lines relative to control-treated [dimethyl sulfoxide (DMSO)] cells as measured by AnnexinV staining (Fig. 1B) . Although the FLT3-ITD AML cell lines were initially sensitive to quizartinib, FLT3-ITD AML cell lines rapidly proliferated after 3 days of quizartinib treatment (Fig. 1B) . To determine whether the leukemic potential of the resistant FLT3-ITD AML cell lines is affected by quizartinib treatment, we examined leukemic progenitor function in vitro and leukemia in vivo.
Adaptively resistant FLT3-ITD AML cell lines recovered 10 days after quizartinib exposure, as demonstrated by formation of leukemic cell colonies in methylcellulose (Fig. 1C) . At the highest dose of quizartinib, the leukemic progenitor function was decreased, which is likely the result of more robust on-target inhibition of FLT3 and potential offtarget effects of quizartinib. Furthermore, resistant MLL-AF9;FLT3-ITD cells that recovered after 30 days of repeated quizartinib exposure rapidly developed leukemia in xenografted NOD.Rag1 −/− ;c null (NRG) mice expressing human IL-3, granulocyte-macrophage colonystimulating factor (GM-CSF), and steel factor (NRGS) at a comparable rate to parental MLL-AF9;FLT3-ITD cells ( fig. S1A ). Repeated exposure of the FLT3-ITD AML cell lines to quizartinib for 30 days revealed a diminished sensitivity to FLT3 inhibition at concentrations sufficient to induce cell death of parental cells ( fig. S1B ). FLT3 and NRAS resequencing confirmed the absence of second-site mutations (F691 and D835) in FLT3 or activating mutations (G12 and G13) in NRAS in the FLT3-ITD AML cell lines resistant to quizartinib treatment, indicating that these cell populations were relying on adaptive signaling resistance mechanisms, rather than acquired mutations ( fig. S1C ). Parallel studies in FLT3-ITD AML cell lines cultured under standard conditions exhibited a similar outgrowth and leukemic potential, suggesting that the presence of cytokines was not the sole (D) Serine-threonine kinase (STK) PamChip analysis was performed on protein lysates isolated from MLL-AF9;FLT3-ITD and MV4;11 cells treated with quizartinib (0.3 nM) for 6 and 12 hours. Hierarchical clustering analysis was performed on differentially phosphorylated peptides in the indicated groups relative to DMSO (two biological replicates). (E) In-cell active kinases inferred from the phosphorylated peptides (STK PamChip) are shown for each of the indicated conditions. (F) Pathway enrichment of differential in-cell kinase activity in MLL-AF9;FLT3-ITD and MV4;11 cells treated with quizartinib for 6 and 12 hours was determined using Panther. (G) Pathway enrichment of differentially expressed genes (>2-fold, P < 0.05) in MLL-AF9;FLT3-ITD cells treated with quizartinib for 12 hours was determined using ToppGene (n = 3 per group).
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mediator of the adaptive resistance ( fig. S1, D and E) . FLT3-ITD AML cell lines cultured under standard conditions or in the presence of cytokines remained sensitive to blockade of FLT3 signaling after treatment with quizartinib ( fig. S1F ), suggesting that the cellular basis of adaptive resistance to FLT3i is mediated by an alternate (non-FLT3-mediated) cell-intrinsic mechanism. Exposure of FLT3-ITD AML cells to the next-generation FLT3i gilteritinib also resulted in cells with competent outgrowth potential, indicating that adaptive resistance is not specific to quizartinib (fig. S1G ). These findings are consistent with eventual failure of FLT3i in the clinic without evidence of acquired FLT3 mutations.
FLT3i induce compensatory innate immune stress responses in FLT3-ITD AML
Resistance of FLT3-ITD AML cells to FLT3i has been attributed to point mutations at or near the adenosine 5′-triphosphate (ATP)-binding domain of FLT3 and to alternate activation of survival and proliferation pathways (1, 2, 22-27, 29, 30) . However, global approaches to delineate the alternate pathways contributing to adaptive resistance in FLT3-ITD AML are lacking. To define mechanisms of adaptive resistance, we examined in-cell kinase activity and gene regulatory networks in adaptively resistant FLT3-ITD AML cells (Fig. 1A) . To identify active signaling cascades in adaptively resistant cells, we subjected protein lysates from MLL-AF9;FLT3-ITD and MV4;11 cells treated with quizartinib [IC 10 (10% inhibitory concentration), 0.3 nM] for 6 and 12 hours in biological duplicates to peptide phosphorylation profiling using commercially available serine-threonine kinase (STK) PamChip arrays. This concentration of quizartinib was selected because it blocks FLT3-ITD signaling and results in adaptively resistant FLT3-ITD AML cells without evidence of cell death, permitting analysis of adaptive responses to FLT3 signaling blockade in the absence of detectable cytotoxic effects. The PamChip arrays generate a dataset of relative phosphorylation propensity of synthetic peptides containing known substrate recognition sites of STKs in the presence and absence of inhibitor. Unsupervised hierarchical clustering analysis using these data identified two major signaling profiles based on the identification of peptides with a relative decrease or increase in phosphorylation after quizartinib treatment for 6 and 12 hours in MLL-AF9;FLT3-ITD and MV4;11 cells ( Fig. 1D and  fig. S2A ). The in-cell active kinases were inferred on the basis of the combination of distinct phosphorylated peptides using the database of STK-substrate pairs from PhosphoNET (www.phosphonet.ca) (table S1 in data file S1). Using a cutoff ( > 3 × 10 −3 ), 46 kinases were activated in both FLT3-mutant AML cell lines after 6 and 12 hours of quizartinib exposure ( Fig. 1E and table S2 in data file S1). To identify the compensatory signaling networks associated with adaptive resistance to FLT3i, we performed functional annotation of the inferred active kinases common to both FLT3-mutant AML cell lines after 6 and 12 hours of quizartinib exposure (table S2) . Using Panther, we identified known compensatory and stress signaling pathways, such as MAPK signaling and dopamine signaling, and several other signaling pathways, including Toll-like receptor (TLR) activation ("innate immune signaling"), that have not previously been implicated in FLT3i adaptive resistance mechanisms to therapy (Fig. 1F) (25, 26, 57) .
In parallel, we performed RNA sequencing (RNA-seq) on MLL-AF9;FLT3-ITD cells treated with quizartinib (IC 10 , 0.3 nM) for 6 and 12 hours. The compensatory transcriptional response involved sets of genes that increased in relative expression after quizartinib treatment for 6 hours [n = 1286; log 2 fold-change (FC) > 2, P < 0.05] and 12 hours (n = 1281; log 2 FC > 2, P < 0.05) in MLL-AF9;FLT3-ITD cells (table S3 in data file S1). The differentially overexpressed genes at 12 hours were enriched in Gene Ontology (GO) pathways related to innate immune signaling (Fig. 1G) , suggesting that compensatory activation of innate immune stress pathways provides a cytoprotective role after FLT3i treatment in FLT3-mutant AML.
Among the critical signaling elements within the innate immune pathway are the IL-1 receptor-associated kinase 1 (IRAK1) and IRAK4, which are upstream of all signaling effectors within the innate immune pathway and are amenable to therapeutic inhibition (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) . A more granular examination of the STK array outcomes highlights that MLL-AF9;FLT3-ITD and MV4;11 cells treated with quizartinib have increased phosphorylation of IRAK1/4-specific peptides ( Fig. 2A) . Orthogonal validation via immunoblotting confirmed increased phosphorylation of IRAK4 at Thr 345 /Ser 346 after inhibition of FLT3-ITD in MLL-AF9;FLT3-ITD or MV4;11 cells by quizartinib (Fig. 2, B and C) . Phosphorylation of IRAK4 was also observed after treatment with the next-generation FLT3i, gilteritinib, in MLL-AF9;FLT3-ITD cells (Fig. 2D ). In these experiments, although the majority of FLT3 signaling is inhibited [as indicated by reduced pFLT3 and phosphorylated signal transducer and activator of transcription 5 (pSTAT5)] (Fig. 2B and fig. S1F ), >95% of quizartinib-treated FLT3-ITD AML cells remained viable (Annexin V − ), strongly suggesting that IRAK1/4 activation is an adaptive survival mechanism. The activation state of IRAK1/4 is durable, and we observed phosphorylated IRAK4 after 72 hours of quizartinib treatment in MV4;11 cells ( fig. S2B ). To determine whether this is an adaptive response based primarily on FLT3 blockade, the isogenic AML cell line MLL-AF9;NRAS G12D , which does not depend on FLT3-ITD oncogenic signaling, was treated with quizartinib at the same dose and time points as the FLT3-ITD line. The NRAS-mutant cells did not exhibit phosphorylation of IRAK4 when treated with quizartinib, suggesting that a dependence on FLT3 signaling is needed to elicit this adaptive response ( fig. S2C ). These observations were extended to patients with FLT3-ITD AML enrolled in a study evaluating the efficacy of gilteritinib (study ID: 2215-CL-9100; table S4 in data file S1). As compared to peripheral blood mononuclear cells (PBMCs) obtained at diagnosis, PBMCs from two patients treated with gilteritinib for 27 and 39 days exhibited increased phosphorylated and total IRAK4 protein, comparable to gilteritinib-treated cells in vitro (Fig. 2D) . As an indication of active IRAK4 signaling, we observed phosphorylated IRAK1 in MV4;11 cells after treatment with quizartinib ( fig. S2D ), a patient after gilteritinib treatment ( fig. S2E) , and BaF3 cells transduced with FLT3-ITD and treated with quizartinib ( fig. S2F ). These findings strongly suggest that FLT3i induce compensatory IRAK1/4 activation in FLT3-ITD AML cells in vitro and in vivo.
To explore a potential mechanism of IRAK1/4 activation in FLT3i-treated FLT3-ITD AML cells, we examined RNA expression after quizartinib treatment of MLL-AF9;FLT3-ITD cells (Fig. 1G) . Because IRAK1/4 is downstream of the TLR superfamily, we compared the expression of all TLRs before and after 6-hour quizartinib treatment. Although six of eight TLRs exhibited increased expression in MLL-AF9;FLT3-ITD cells after quizartinib treatment, only TLR9 was significantly overexpressed at 6 hours and remained elevated at 12 hours (P = 0.019, adjusted) ( fig. S3, A and B) . Immunoblotting of MLL-AF9;FLT3-ITD cells treated with quizartinib revealed that inhibition of FLT3-ITD increases the expression of cleaved TLR9, which has been associated with its active state ( fig. S3C) (70, 71) . To establish whether increased TLR9 expression and activation in quizartinib-treated FLT3-ITD AML cells result in IRAK1/4 activation, we treated MLL-AF9;FLT3-ITD simultaneously with quizartinib and a TLR9 antagonist (30 nM; ODN-INH-18). In the presence of the TLR9 antagonist, quizartinib-mediated activation of IRAK4 was suppressed as compared to MLL-AF9;FLT3-ITD cells treated only with quizartinib ( fig. S3D ). Increased expression of TLRs, such as TLR9, on FLT3i-treated AML cells may account for the activation of innate immune pathways in adaptively resistant FLT3-ITD AML cells.
Innate immune signaling via IRAK1/4 is required for adaptive resistance of FLT3-ITD AML to FLT3i
We next investigated whether IRAK1/4 activation is a functionally required element of adaptive resistance of FLT3-ITD AML to FLT3i. Several published inhibitors of IRAK1/4 exist, providing key tools to assess the role of IRAK1/4 in adaptive diseases (69, 72, 73) . We first evaluated a pairwise matrix combination of quizartinib and a commercially available IRAK1/4 inhibitor (IRAK-Inh) in MLL-AF9;FLT3-ITD cells (74) . This experiment used a 48-hour CellTiter-Glo assay format to demonstrate that the combination of quizartinib and IRAK-Inh is synergistically cytotoxic in MLL-AF9;FLT3-ITD cells (Fig. 2E ). Even at low doses of quizartinib (0.3 or 0.4 nM), inhibition of IRAK1/4 decreased MLL-AF9;FLT3-ITD cell viability more than would be expected as an additive response ( Fig. 2E and fig. S4A ). 
Small-molecule inhibitors were generated to simultaneously target IRAK1/4 and FLT3
The immediate nature of IRAK1/4 activation in adaptively resistant FLT3-ITD AML cells requires concomitant inhibition of these targets to avoid compensatory signaling and cell survival. Achieving optimal multidrug combination regimens that yield extended overlapping exposure while avoiding unwanted toxicities is challenging. Therefore, we desired a small-molecule inhibitor that simultaneously targeted the FLT3 and IRAK1/4 kinases to eradicate adaptively resistant FLT3-ITD AML. Inhibition of FLT3 is a common "off-target" pharmacology for many advanced kinase inhibitors (cabozantinib, sorafenib, and ponatinib). We therefore considered previously reported IRAK1/4 inhibitors as potential starting points for the optimization of a dual FLT3/IRAK inhibitor. Among the more promising candidates were a series of 3-(pyridin-2-yl)imidazo[1,2-a]pyridines that were previously reported as selective IRAK4 inhibitors and appeared to be attractive chemical starting points for optimization as dual FLT3/IRAK inhibitors (72) . Structure activity relationship exploration around this core scaffold yielded a series of small molecules that potently targeted IRAK1, IRAK4, and FLT3. In a functional biochemical assay, three of these agents (NCGC2376, NCGC2327, and NCGC1410) inhibited FLT3 at subnanomolar concentrations (IC 50 < 0.5 nM) and IRAK1 and IRAK4 at low nanomolar concentrations (Fig. 3, A and B) . Whereas the three compounds were equipotent FLT3i (IC 50 < 0.5 nM), their relative efficacies at inhibiting FLT3-ITD AML cell viability correlated with their IRAK1/4 inhibitory potencies (Fig. 3, B and C) . Thus, the most potent IRAK1/4 inhibitor NCGC2327 (IRAK1 IC 50 = 1.6 nM; IRAK4 IC 50 < 0.5 nM) was the most efficacious at inhibiting MLL-AF9;FLT3-ITD cell growth, and the weakest IRAK1/4 inhibitor NCGC1410 (IRAK1 IC 50 = 636 nM; IRAK4 IC 50 = 8.7 nM) was correspondingly less efficacious (Fig. 3C) . Moreover, NCGC2327 and NCGC2376 were more effective at suppressing MLL-AF9;FLT3-ITD leukemic cell recovery relative to NCGC1410, as measured by AnnexinV staining (Fig. 3D) , suggesting that potency against IRAK1/4 is a driving element for suppressing adaptively resistant FLT3-ITD AML cells. The finding that NCGC1410 retained potency against IRAK4 yet was less effective at suppressing MLL-AF9;FLT3-ITD AML cells than NCGC2376, which inhibits IRAK1 and IRAK4, argues that targeting both kinases is necessary to achieve optimal suppression of FLT3-mutant AML. NCGC2327 also effectively suppressed FLT3-ITD signaling and compensatory activation of IRAK4 in MLL-AF9;FLT3-ITD cells and was more effective at preventing compensatory activation of IRAK4 as compared to simultaneously inhibiting FLT3 and IRAK1/4 with a combination of quizartinib and IRAK-Inh (Fig. 3E ). These findings indicate that the efficacy of suppressing FLT3-ITD AML with an FLT3i correlates with concomitant targeting of IRAK1 and IRAK4. Continued optimization of these agents led to the identification of NCGC1481, which retained strong biochemical potency versus FLT3, IRAK1, and IRAK4 while also displaying acceptable pharmacokinetic properties in mice (Fig. 4A and fig. S5 ). (Fig. 4B) . Consistent with our data that NCGC1481 also inhibits FLT3, we have obtained a crystal structure of the NCGC1481-FLT3 complex (PDB: 6IL3). Sequence alignment and two-dimensional (2D) interaction diagrams derived from these structures highlight conserved binding elements between IRAK4 and FLT3 and show that the FLT3 ATP-binding domain is relatively more permissive, which is consistent with the fact that FLT3 is routinely found as an off-target pharmacology for multiple kinase inhibitors ( fig. S6 ). When profiled against 369 kinases using Reaction Biology biochemical inhibition assays, NCGC1481 demonstrated modest selectivity (10-fold or greater selectivity versus more than 80% of tested kinases relative to IRAK1, IRAK4, and FLT3) with strong activity noted versus Src-family kinases and selected classes of receptor tyrosine kinases (Fig. 4C and table S5 in data file S1). Given the known caveats of relying on biochemical assays to decipher kinome selectivity, we felt that it was critical to establish the in situ kinome selectivity for this class of agents in relevant cells (75) . We therefore submitted NCGC1481 to the KiNativ in situ kinase profiling platform. Examination of NCGC1481 in MV4;11 revealed a higher kinase selectivity in situ relative to the selectivity observed in biochemical assays using purified active proteins (Fig. 4, D and E, and table S6 in data file S1). Of the 259 expressed and active kinases in MV4;11 cells, only 12 were inhibited with an IC 50 value of less than 250 nM (Fig. 4E) . We next sought to delineate which of these kinase targets contribute to the cytotoxicity of NCGC1481. For this, we generated a series of analogs of NCGC1481 with varying potency against the 12 top kinase targets based on biochemical inhibition assays and then evaluated each analog's cytotoxicity in MV4;11 cells (Fig. 4F) . On the basis of this analysis, the more highly correlated contributing targets to the cytotoxicity of MV4;11 cells are FLT3 (R 2 = 0.79), IRAK4 (R 2 = 0.70), and LYN (R 2 = 0.87). IRAK1 also shows correlation between potency and cytotoxicity, but the potency decline between NCGC2376 and NCGC1410 is ~35-fold, whereas the cytotoxicity decline between these two analogs is only 2-fold. Although LYN was inhibited by NCGC1481 in the biochemical assays, NCGC1481 exhibited only moderate effects on the phosphorylation status of LYN at the doses at which FLT3 and IRAK1/4 were inhibited in MV4;11 cells ( fig. S7A ), suggesting that inhibition of FLT3 and IRAK4 primarily contributes to the cytotoxicity of NCGC1481. Notwithstanding, most small-molecule kinase inhibitors target more than one kinase, and it is often the collective inhibition of multiple signaling nodes that contributes to the broad biological effects of a kinase inhibitor. Additional assays further demonstrated that NCGC1481 inhibited phosphorylation of FLT3 and IRAK4 and IRAK1/4-mediated nuclear factor B (NF-B) transcriptional activation in a time-and dose-dependent manner ( fig. S7, B and C) . Moreover, NCGC1481 exhibits attractive physical properties, including good aqueous solubility, cell permeability, metabolic stability, and low activity in selected in vitro-based toxicity-associated target assay ( fig. S5, A and B) .
To demonstrate that NCGC1481 is selective for AML cells dependent on FLT3 signaling, we measured proliferation of isogenic AML cells lines derived from primary CD34 + human cord blood cells transduced with MLL-AF9 and then transduced with NRAS G12D or FLT3-ITD (45). MLL-AF9;FLT3-ITD cells were highly sensitive to NCGC1481 (IC 50 = 0.1 nM), whereas MLL-AF9;NRAS G12D cells were less responsive to NCGC1481 (IC 50 = 573 nM) (Fig. 4G) . The parental MLL-AF9 cells exhibited an intermediate sensitivity to NCGC1481 (IC 50 = 4.9 nM) because these cells are dependent on wild-type FLT3 signaling (Fig. 4G ) (45) . As expected, NCGC1481 suppressed the short-term proliferation of MLL-AF9;FLT3-ITD, MV4;11, and MOLM13 cells ( fig. S7D) . In a panel of 13 primary AML patient samples, NCGC1481 was primarily effective against FLT3-mutant AML while exhibiting minimal activity against FLT3-wild type AML (Fig. 4H and table S7 in data file S1).
Collectively, these data demonstrate (i) the importance of concomitant in vitro and in situ kinase target profiling; (2) that NCGC1481 is highly effective at targeting FLT3, IRAK1, and IRAK4 in FLT3-ITD mutant AML cells; and (3) that inhibition of these targets correlates with the cytotoxicity of NCGC1481.
NCGC1481 inhibits IRAK1/4 and compensatory innate immune signaling in FLT3-ITD AML cells
The system-level differences associated with simultaneous IRAK1/4 and FLT3 inhibition versus selective inhibition of FLT3 were next examined in FLT3-ITD AML cells. We first confirmed, via immunoblotting for pIRAK4 and pFLT3, that NCGC1481 simultaneously inhibited IRAK4 and FLT3, whereas quizartinib induced activation of IRAK4 upon inhibition of FLT3 in the appropriate cell models (MLL-AF9;FLT3-ITD and MV4;11) (Fig. 5A and fig. S7B ). We thereafter collected protein lysates from MLL-AF9;FLT3-ITD and MV4;11 cells treated with NCGC1481 (0.1 nM, IC 10 ) for 6 and 12 hours and subjected these samples to PamChip peptide phosphorylation profiling. Our ability to contrast these outcomes with the data generated in the same cells after quizartinib treatment (Fig. 1) offered insight into the divergent cellular response to these agents (table S8 in data file S1). The set of peptides with increased phosphorylation intensity after 12 hours of quizartinib treatment showed decreased phosphorylation in NCGC1481-treated MLL-AF9;FLT3-ITD and MV4;11 cells (Fig. 5B) . Inspection of the IRAK1/4-specific peptides revealed that IRAK1 and IRAK4 activation was also inhibited after 6 and 12 hours of NCGC1481 treatment as compared to quizartinib (Fig. 5C) in FLT3-ITD AML cells at 6 and 12 hours (Fig. 5D and tables S3 and S9 in data file S1). Gene expression profiling by RNA-seq in MLL-AF9;FLT3-ITD cells treated with NCGC1481 (0.1 nM), quizartinib (0.3 nM), or DMSO showed that genes up-regulated by quizartinib, but not NCGC1481, at 12 hours were enriched for interleukin (P = 0.0021) and inflammation signaling (P = 0.030) by ToppGene analysis (Fig. 5E) . Because quizartinib induced genes and kinases associated with immune signaling pathway activation, we determined whether MAPKs, which are implicated as compensatory pathways in FLT3i-treated AML cells, are regulated by IRAK1/4. On the basis of the in-cell kinase analysis, quizartinib-treated MLL-AF9;FLT3-ITD cells exhibited compensatory activation of Ras/MAPK and PI3K/AKT pathways (Fig. 5F ). In contrast, NCGC1481-treated MLL-AF9;FLT3-ITD cells did not reactivate these kinases (Fig. 5F ). 
NCGC1481 prevents adaptive resistance of FLT3-ITD AML in vitro
We next investigated whether NCGC1481 can suppress the adaptive resistance of FLT3-ITD AML in vitro. NCGC1481 treatment of MLL-AF9;FLT3-ITD, MV4;11, or FLT3-ITD AML patient-derived cells abolished the outgrowth of adaptively resistant FLT3-ITD AML cells as compared to quizartinib (Fig. 6A ). NCGC1481 treatment did not inhibit the viability and progenitor function of normal CD34 + BM cells after 72 hours of treatment and 7 days of recovery (Fig. 6, B and C) . MLL-AF9;FLT3-ITD and MV4;11 cells recovered 10 days after inhibitor exposure were plated in methylcellulose to assess leukemic cell potential. The recovered MLL-AF9;FLT3-ITD and MV4;11 cells treated with NCGC1481 did not form any leukemic colonies, whereas quizartinib-treated recovered cells maintained their leukemic potential (Fig. 6D) . In a direct comparison to gilteritinib, NCGC1481 was more effective at suppressing adaptively resistant MV4;11 cells ( fig. S8, A and B) . We also noted that the leukemic cell potential of parental FLT3-ITD AML cells was diminished by NCGC1481 relative to quizartinib or DMSO ( fig. S8C ), which coincided with drug-stimulated induction of apoptosis ( fig. S8D ). NCGC1481 did not affect colony formation of healthy cord blood CD34 + cells or adult CD34 + BM cells at equivalent or even higher concentrations ( fig. S8E) .
Given the efficacy of NCGC1481 in suppressing adaptive resistance in naïve FLT3-ITD AML cells, we asked whether NCGC1481 remained effective at inhibiting adaptively resistant FLT3-ITD AML cells after treatment with quizartinib. Prior exposure of MV4;11 cells to quizartinib for 3 days followed by 7 days of recovery in fresh medium resulted in diminished sensitivity to re-exposure with quizartinib even at increased concentrations (IC 50 = not achieved) (Fig. 6E) . In contrast, NCGC1481 remained effective at eliminating adaptively resistant FLT3-ITD AML cells after primary exposure to quizartinib (IC 50 = 230 nM) (Fig. 6E) . This effect was mediated by inhibition of FLT3 and IRAK1/4, and the IRAK-Inh alone was insufficient for suppressing the viability of adaptively resistant FLT3-ITD AML (Fig. 6E) . As an orthogonal approach, after 3 days of exposure to quizartinib (5 M) followed by 7 days of recovery, MLL-AF9;FLT3-ITD cells were either exposed to quizartinib (5 M) or NCGC1481 (5 M). After 10 days, the recovered MLL-AF9;FLT3-ITD cells were treated again with quizartinib or NCGC1481. Although repeated exposure of MLL-AF9;FLT3-ITD cells to quizartinib resulted in diminished sensitivity to quizartinib at concentrations sufficient to induce cell death of parental cells, NCGC1481 remained effective at eliminating adaptively resistant FLT3-ITD AML cells in culture after the primary or secondary exposure to quizartinib (Fig. 6F) . To assess whether a similar effect of NCGC1481 was observed in FLT3-ITD AML patient-derived cells, we treated primary FLT3-ITD AML cells with quizartinib (5 M), which resulted in an acute drop in viable cells that began to recover after day 3. After 7 days, the recovered FLT3-ITD AML cells were treated again with quizartinib (5 M) or NCGC1481 (5 M). In this setting, primary FLT3-ITD AML cells were moderately sensitive (relative to vehicle-treated cells) to quizartinib retreatment, whereas treatment with NCGC1481 significantly reduced the number of viable FLT3-ITD AML cells (P = 0.027; Fig. 6G ).
NCGC1481 effectively targets resistant FLT3-ITD AML xenografts
Last, we assessed the in vivo antileukemic activity of NCGC1481. NCGC1481 exhibits suitable pharmacokinetic properties in mice for once-daily intraperitoneal dosing and does not result in hematologic toxicity ( fig. S5, C to E) . The antileukemic activity of NCGC1481 was initially assessed on parental and quizartinib-refractory MLL-AF9;FLT3-ITD cells intravenously injected into NRGS mice, which develop aggressive disseminated AML (Fig. 6H) (76, 77) . After 48 hours, phosphorylated IRAK4 and FLT3 were lower in MLL-AF9;FLT3-ITD cells isolated from mice treated with NCGC1481 (30 mg/kg per day) as compared to mice receiving vehicle (Fig. 6I) . At the same dose, NCGC1481 administration significantly extended the overall median survival of mice xenografted with parental MLL-AF9;FLT3-ITD cells from 40 to 49 days (P = 0.0026; Fig. 6J ). NCGC1481 also significantly extended the overall median survival of mice xenografted with quizartinib-recovered MLL-AF9;FLT3-ITD cells from 34 to 53 days (P = 0.0068; Fig. 6J ). Mice were euthanized when they exhibited physical symptoms of leukemia such as reduced motility, rough coat, and hunched posture. At the time of euthanasia, leukemic burden [percent green fluorescent protein (GFP)] in the BM (88.4 ± 5.7% versus 70.1 ± 12.8%) and spleen (79.3 ± 8.2% versus 51.4 ± 19%) was reduced after treatment with NCGC1481 as compared to vehicletreated mice ( fig. S9A) . In a second approach, we compared the antileukemic effects of NCGC1481 and quizartinib using FLT3-mutant AML cells from patients with refractory leukemia (AML-174 and AML-019). NSGS mice were intravenously xenografted with AML-174 or AML-019 cells and then dosed with NCGC1481 (30 mg/kg per day), quizartinib (15 mg/kg per day), or vehicle (Fig. 6K) . These doses were chosen to correct for the disparity in exposure concentration and half-life (T 1/2 ) (NCGC1481: AUClast = 6750 hours × ng/ml and T 1/2 = 4.2 hours; quizartinib: AUClast = 155 hours × g/ml and T 1/2 = 5.7 hours; fig. S5C ). After confirming engraftment of AML-174 cells (day 0) and then after 14 days of treatment, NCGC1481 afforded a 38 and 48% reduction in leukemic burden in the BM as compared to mice receiving vehicle or quizartinib, respectively (Fig. 6L) . After 28 days of treatment, mice that were treated with NCGC1481 exhibited a 66 and 50% reduction in leukemic burden in the BM as compared to mice receiving vehicle or quizartinib, respectively (Fig. 6L) . Moreover, the frequency of CD34 + AML cells in the BM (P = 0.0011) and spleen (P = 0.00016) was significantly reduced after NCGC1481 administration as compared to control mice ( fig. S9B ), indicating that NCGC1481 has an effect on disease-propagating AML cells. In this model, NCGC1481 significantly extended the overall median survival to 90 days compared to 66.5 days for mice receiving vehicle (P = 0.0016) or 76 days for mice receiving quizartinib (P = 0.0097) (Fig. 6M) . For mice xenografted with AML-019 cells, NCGC1481 administration also significantly extended the overall median survival of mice (P = 0.0021; Fig. 6N ). As compared to vehicle (median survival = 57 days) or quizartinib (median survival = 64 days), most of the mice treated with NCGC1481 did not succumb to leukemia beyond 94 days of treatment, at which time the experiment was terminated (Fig. 6N) . Last, we wanted to determine whether NCGC1481 can reduce the leukemic burden of mice treated with quizartinib. NSGS mice were intravenously xenografted with AML-174 cells and then dosed with quizartinib (15 mg/kg per day) for 43 days and then either continued on quizartinib or switched to NCGC1481 for an additional 14 days (fig. S10A ). After 43 days of quizartinib treatment, the leukemic burden in the mice was approximately 18% (fig. S10B ). For the mice that continued on quizartinib treatment, the leukemic burden in the BM increased from 18 to 54% ( fig. S10B) , whereas for the mice that were switched to NCGC1481, the leukemic burden increased only from 17 to 43% (fig. S10B ). The mice that were switched to NCGC1481 did not exhibit a significant change in the CD34 + leukemic stem cell population as compared to mice that continued on quizartinib treatment (P = 0.12; fig. S10C ). response rates to FLT3i in clinical studies for FLT3-mutant leukemia; however, patients eventually relapse with FLT3i-resistant clones (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The absence of durable remission in patients with FLT3-mutant leukemia treated with potent and selective FLT3i establishes the need to identify resistance mechanisms and develop additional treatment strategies. Here, we identified mechanisms of adaptive resistance to targeted inhibitors in AML associated with activating FLT3 mutations. Our results suggest that FLT3i adaptive resistance occurs through compensatory activation of innate immune stress pathways in FLT3-mutant AML and that inhibition of IRAK1/4 with FLT3i targets the emergence of adaptively resistant mutant clones. Specifically, activation of IRAK1/4 in FLT3i-treated AML restored Ras/MAPK signaling along with NF-B, which represents a major mechanism of resistance after tyrosine kinase inhibition (1, (24) (25) (26) 78) . Cellular stress responses are survival mechanisms activated by cells. Although stress pathways have been extensively characterized, recent studies have shown that proteins in cellular stress responses interact with and regulate signaling intermediates involved in the activation of immune-related pathways (79) . Although we report that FLT3i treatment resulted in TLR9 overexpression and IRAK1/4 activation, the precise mechanism of innate immune signaling and specifically IRAK1/4 activation after targeted therapy is not resolved and may involve various cellular stress response pathways. Cellular stresses associated with FLT3i treatment, such as oxidative stress, heat shock, unfolded protein, and DNA damage responses have been independently shown to activate innate immune signaling, albeit by distinct mechanisms (67, (80) (81) (82) (83) (84) (85) (86) (87) . In addition to overexpression of certain TLRs, gene expression analysis of FLT3i-treated cells also revealed overexpression of TLR ligands and inflammatory cytokines. In such conditions, fractional cell death and/or cellular stress after FLT3i treatment can result in the release of inflammatory mediators that subsequently induce innate immune signaling and IRAK1/4 activation, such as via TLR9. Therefore, one potential mechanism of compensatory activation of the innate immune stress pathway in FLT3i-resistant AML subclones is through paracrine and autocrine activation of IRAK1/4. We also observed a modest, yet consistent, increase in IRAK4 expression after prolonged FLT3i treatment of FLT3-mutant AML cells in vitro and in vivo. Consistent with the idea that increased IRAK4 expression correlates with adaptive resistance, retroviral overexpression of IRAK4 decreased the sensitivity of FLT3-ITD AML cells to FLT3i. Thus, another potential mechanism of compensatory activation of the innate immune stress pathway in FLT3i-resistant AML subclones may occur as a result of IRAK1/4 overexpression.
DISCUSSION
There are ongoing efforts to suppress activation of parallel signaling pathways, such as MAPK kinase and extracellular signalregulated kinase, after prolonged exposure to targeted therapies (31-33, 36, 37, 42, 88) . Ras/MAPK signaling is responsible for adaptively resistant FLT3-mutant AML; however, targeting only a single arm of the signaling cascade has yielded limited clinical benefit (NCT02418000). Because IRAK1/4 complex is upstream of Ras/MAPK and NF-B (58), we posit that targeting IRAK1/4 will yield more durable inhibition of bypass signaling cascades, prevent adaptive resistance, and result in improved therapeutic efficacy in FLT3-mutant AML. Although IRAK1 or IRAK4 inhibition has been explored in myelodysplastic syndrome, AML, T cell acute lymphoblastic leukemia, and lymphoma, albeit with limited efficacy, we present evidence that innate immune pathway activation via IRAK1 and IRAK4 is essential for adaptive resistance to therapy (64, 66, 69, 73, 89, 90) . Our data suggest that concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when targeting FLT3. Gilteritinib, which exhibits modest inhibition of IRAK1/4 at higher concentrations, is less effective at suppressing adaptive resistance to therapy in FLT3-mutant AML as compared to NCGC1481, which potently targets IRAK1 and IRAK4. To overcome the current limitations of FLT3i, we report a polypharmacologic strategy and a multitarget small molecule with potent activity against the IRAK1/4 complex and FLT3, which suppresses adaptive resistance to therapy in FLT3-mutant AML by targeting inflammatory stress response pathways.
Given the restrictions of using patient-derived samples for functional studies, it was necessary to confirm the adaptive resistance mechanism via innate immune pathway activation and validate NCGC1481 in independent FLT3-mutant AML cell lines. However, cell lines may not accurately represent the complexity of adaptive resistance mechanisms to FLT3i in patients, arguing for cautious interpretation of these data. Furthermore, the current experimental design is limited to adaptive resistance mechanisms occurring immediately after FLT3i treatment, and it should be noted that adaptive resistance mechanisms after prolonged FLT3i treatment may differ.
Here, we identified activation of innate immune stress response pathways after treatment of FLT3-mutant AML cells with FLT3i. Although further studies are needed, our study demonstrates that therapies that simultaneously inhibit FLT3 signaling and compensatory IRAK1/4 activation have the potential to improve the therapeutic efficacy in patients with FLT3-mutant AML. We demonstrate that inflammatory stress response pathways contribute to adaptive resistance in FLT3-mutant AML and propose that this mechanism may extend to other malignant cells undergoing a stress-induced response to therapy.
MATERIALS AND METHODS
Study design
The first objective of this study was to find target-independent mechanisms of resistance, such as alternate activation of survival and proliferation pathways (adaptive resistance), to FLT3 inhibition in FLT3-mutant AML by performing an integrative in-cell kinase (PamChip kinase array) and gene regulatory network (RNA-seq) analysis. The second objective was to identify an inhibitor with the potential of suppressing FLT3-ITD and the pathway contributing to adaptive resistance in FLT3-mutant AML. To overcome adaptive resistance to FLT3 inhibition, we synthesized a series of small molecules to inhibit the compensatory pathway activation contributing to adaptive resistance (via IRAK1/4) and FLT3 in FLT3-mutant AML. The chemical starting points for optimization of IRAK1/4 and FLT3 smallmolecule inhibitors were based on the 3-(pyridin-2-yl)imidazo [1,2-a] pyridines that were previously reported as selective IRAK4 inhibitors. The potency and selectivity of the inhibitors were determined by biochemical binding and inhibitory assays and in situ kinase profiling. The optimized small-molecule inhibitor (NCGC1481) was confirmed by cocrystallography to bind IRAK4 in an inactive confirmation. In-cell kinase (PamChip kinase array) assays, immunoblotting, and gene expression profiling confirmed that NCGC1481 simultaneously suppresses FLT3 and IRAK1/4 in FLT3-mutant AML. The therapeutic benefit of targeting IRAK1/4 and FLT3 in FLT3-mutant AML with NCGC1481 as compared to a selective FLT3i was confirmed in human cell lines and patient-derived samples in vitro and in vivo. Existing deidentified cryopreserved samples were used for the study without age or gender preferences. Investigators and data analyzers were blinded for the evaluation of NCGC1481 in primary patient-derived AML samples in vitro. Mouse experiments were planned in an effort to provide 60 to 80% power for a target effect size of 1.2 to 1.5 (effect size = |mean difference|/SD). All mice were randomly allocated into experimental groups. For all other experiments, at least two independent biological replicates were performed and used in the sample calculation. No data were excluded from the studies.
Cell lines, patient samples, and culture conditions MLL-AF9 FLT3-ITD and MLL-AF9 NRAS G12D cell lines, provided by J.C.M., were cultured in Iscove's Dulbecco's modified Eagle's medium (Corning Cell Grow, catalog no. 10-016-CV) with 20% fetal bovine serum (FBS) (Atlanta Biologicals, catalog no. S11550) and 1% penicillinstreptomycin (P/S) (HyClone, catalog no. SV30010) (45) . MV4;11 cell line was provided by L. Grimes [Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH] and purchased from American Type Culture Collection (ATCC) (catalog no. CRL-9591). The cells were cultured in RPMI 1640 medium with 10% FBS and 1% P/S. MOLM13 cell line, purchased from AddexBio (catalog no. C0003003), was cultured in RPMI 1640 medium (HyClone, catalog no. SH30027.01) with 20% FBS and 1% P/S. THP1-Blue NF-B reporter cells were obtained from InvivoGen (catalog no. thp-nfkb) and grown according to the manufacturer's instructions. BaF3 cells were provided by M. Azam (CCHMC, Cincinnati, OH) and purchased from ATCC (catalog no. HB-283). They were cultured in RMPI 1640 medium with 10% FBS, 1% P/S, and recombinant murine IL-3 (PeproTech, catalog no. 213-12-50UG) (all at 10 ng/ml). Human CD34 + umbilical cord blood, human CD34 + BM, and human normal whole BM were obtained from the Translational Research Development Support Laboratory of Cincinnati Children's Hospital under an approved Institutional Review Board protocol. These cells were maintained in StemSpan serum-free expansion medium (STEMCELL Technologies, catalog no. 09650) supplemented with recombinant human SCF (10 ng/ml; PeproTech, catalog no. 300-07-50UG), recombinant human TPO (PeproTech, catalog no. 300-18-50UG), recombinant human FLT3 ligand (FL) (PeproTech, catalog no. 300-19-50UG), recombinant human IL-3 (PeproTech, catalog no. 200-03-50UG), and recombinant human IL-6 (PeproTech, catalog no. 200-06-50UG). AML primary patient samples were obtained with written informed consent and approved by the Institutional Review Board of CCHMC. These samples had been obtained within the framework of routine diagnostic BM aspirations after written informed consent in accordance with the Declaration of Helsinki. AML-019 was purchased from the Public Repository of Xenografts (catalog no. DFAM-16835-V1). Analysis of short tandem repeat loci was performed on all cell lines when received and after experimentation was complete. All cell lines were routinely tested and were confirmed to be negative for mycoplasma.
Lenti-and retroviral infections
The pLKO.1 (Open BioSystems) constructs were obtained from the Viral Vector Core at CCHMC and used to express shCTL and shIRAK4 (TRCN0000002065). Puromycin resistance gene was replaced by GFP. The pGreenFire1-NF-B (EF1-puro) lentivector was purchased from System Biosciences (catalog no. TR012VA-P). Flag-IRAK4 in pMSCV-pGK-GFP was designed as previously described (90) . Cells were transduced as previously described (91) .
RNA sequencing RNA was isolated using Quick-RNA MiniPrep (Zymo Research, catalog no. R1055) from MLL-AF9;FLT-ITD cells treated with DMSO, quizartinib (0.3 nM), or NCGC1481 (0.1 nM) for 6 and 12 hours in biological triplicates. RNA libraries were prepared according to the Illumina TruSeq Stranded mRNA (polyA capture) library protocol by the DNA Sequencing and Genotyping Core at CCHMC. The data discussed in this publication have been deposited in National Center for Biotechnology Information's (NCBI's) Gene Expression Omnibus (GEO) and are accessible through GEO series accession no. GSE121272.
Quantitative high-throughput drug screening MLL-AF9;FLT3-ITD cells were grown in Iscove's modified Dulbecco's medium (IMDM) (Thermo Fisher Scientific, catalog no. 12440-061) supplemented with 20% FBS (STEMCELLTechnologies, catalog no. 06100), 1% P/S (Thermo Fisher Scientific, catalog no. 15140122) with recombinant human SCF (PeproTech, catalog no. 300-07-50UG), recombinant human TPO (PeproTech, catalog no. 300-18-50UG), recombinant human FLT3 ligand (FL) (PeproTech, catalog no. 300-19-50UG), recombinant human IL-3 (PeproTech, catalog no. 200-03-50UG), and recombinant human IL-6 (PeproTech, catalog no. 200-06-50UG) (all at 10 ng/ml). MLL-AF9;FLT3-ITD cells were maintained in IMDM supplemented with 20% FBS and no growth factors. Cells were plated at a density of 500 cells per well in 5 l of complete growth medium in 1536-well white tissue culture assay plates (Greiner). Compounds (23 nl) were then added to each assay plate using a PinTool Dispenser (Kalypsys). Plates were then covered with a stainless steel gasketed lid and placed into an incubator in 37°C and 5% CO 2 for 48 hours. After this incubation, 3 l of CellTiter-Glo reagent was added to each well and then incubated for 15 min at room temperature. Luminescence readings were taken using a ViewLux (PerkinElmer) with clear filter and a 2-s exposure time. Curve fitting was done using a four-parameter Hill slope equation (GraphPad Prism 7).
STK array and analysis
MLL-AF9 FLT3-ITD or MV4-11 cells were treated for 6 or 12 hours with quizartinib (0.3 nM), NCGC-1481 (0.1 nM), or DMSO. Whole-cell lysates were prepared according to PamGene instructions (protocol 1160). PamChip STK array was performed by PamGene. From 144 nonredundant peptides, individual peptide phosphorylation intensities were normalized to DMSO control and log-transformed. Peptides determined to have significant increased or decreased phosphorylation (P < 0.05) were used to infer active STKs. The database of potential upstream STKs was downloaded from PhosphoNET (www.phosphonet.ca). A given STK-substrate pair was considered highly probable if its Kinexus predictor score (v2) was greater than 300. The PamChip peptide data were integrated with the PhosphoNET kinase-substrate network to calculate kinase specificity scores (using 2000 permutations across target peptides) and the kinase scores (using 2000 permutations across sample labels). The kinases were then prioritized on the basis of the sum of the two scores.
Pathway and network analyses
Of the inferred kinases showing increased activity in the PamGene assay in AC200 relative to DMSO, 46 were common to both the MLL-AF9;FLT3-ITD and MV4-11 cells lines at both 6 and 12 hours. These kinases were analyzed using ToppFun in the ToppGene Suite (https://toppgene.cchmc.org/) to determine enriched signaling pathways. ClueGo (v2.5.1) was used to create the network map (ontology = GO biological processes, network specificity = medium; P < 0.05). Mice were monitored by BM aspirate and observed for physical attributes of disease, such as limb paralysis, fatigue, and rough fur. NCGC-1481 and quizartinib were prepared in DMSO and further dissolved in sterile phosphate-buffered saline. Animals were intraperitoneally injected with NCGC-1481 (30 mg/kg) or quizartinib (15 mg/kg) 5× weekly. All mice were bred, housed, and handled in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of CCHMC. The study is compliant with all relevant ethical regulations regarding animal research.
Xenografts
Statistical analysis
The numbers of animals, cells, and experimental replicates can be found in the figure legends. Differences among multiple groups were assessed by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison post test for all possible comparisons. Comparison of two groups was performed using a Student's t test (unpaired, two-tailed) or Mann-Whitney test when sample size allowed. Significance was set at P < 0.05. Unless otherwise specified, results are depicted as the means ± SEM. D'Agostino and Pearson and Shapiro-Wilk tests were performed to assess data distributions. For Kaplan-Meier analysis, Mantel-Cox test was used. Data were analyzed and plotted using GraphPad Prism 7 software. Original data are provided in data file S2.
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